Literature DB >> 15577450

Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma.

Jonathan J Beitler1, Denise Makara, Phillip Silverman, Gil Lederman.   

Abstract

INTRODUCTION: Localized renal cell carcinoma is conventionally treated surgically. Preoperative and adjuvant external radiation have not improved survival. However, renal cell cancer brain metastases, although radioresistant to conventional external radiation, have been responsive to radiosurgery. The following report was compiled with information from our experience using high-dose-per-fraction, conformal radiation delivered to patients who refused definitive surgery.
MATERIALS AND METHODS: Nine patients with nonmetastatic renal cell carcinomas were identified, 2 of which had bilateral renal cell cancers. Patients were treated definitively with 40 Gy in 5 fractions using conformal external radiation.
RESULTS: With a median follow up of 26.7 months, 4 of the 9 patients are alive. The survivors have a minimum follow up of 48 months. At presentation, all 4 of the survivors had tumors < or =3.4 cm in largest dimension, had clinically negative nodes, and presented no clinical evidence of penetration of Gerota fascia or renal vein extension.
CONCLUSION: High-dose-per-fraction, conformal external radiation may have a curative role for small, node-negative, organ-confined renal cell carcinomas.

Entities:  

Mesh:

Year:  2004        PMID: 15577450     DOI: 10.1097/01.coc.0000145289.57705.07

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  20 in total

Review 1.  Extracorporeal stereotactic radiosurgery for small renal masses.

Authors:  Gino J Vricella; Nicholas A Boncher; Lee E Ponsky
Journal:  Curr Urol Rep       Date:  2010-02       Impact factor: 3.092

Review 2.  To combine or not combine: the role of radiotherapy and targeted agents in the treatment for renal cell carcinoma.

Authors:  Christian Weiss; Björn Schulze; Annette Ottinger; Claus Rödel
Journal:  World J Urol       Date:  2013-05-08       Impact factor: 4.226

Review 3.  Stereotactic body radiation therapy: a novel treatment modality.

Authors:  Simon S Lo; Achilles J Fakiris; Eric L Chang; Nina A Mayr; Jian Z Wang; Lech Papiez; Bin S Teh; Ronald C McGarry; Higinia R Cardenes; Robert D Timmerman
Journal:  Nat Rev Clin Oncol       Date:  2009-12-08       Impact factor: 66.675

4.  A survey of stereotactic body radiotherapy use in the United States.

Authors:  Hubert Pan; Daniel R Simpson; Loren K Mell; Arno J Mundt; Joshua D Lawson
Journal:  Cancer       Date:  2011-03-15       Impact factor: 6.860

Review 5.  Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy.

Authors:  Cédric Panje; Nikolaus Andratschke; Thomas B Brunner; Maximilian Niyazi; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2016-10-24       Impact factor: 3.621

6.  Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus.

Authors:  Raquibul Hannan; Vitaly Margulis; Stephen G Chun; Nathan Cannon; D W Nathan Kim; Ramzi E Abdulrahman; Arthur Sagalowsky; Ivan Pedrosa; Hak Choy; James Brugarolas; Robert D Timmerman
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

7.  Proton Therapy for Primary Renal Cell Carcinoma: The First Nationwide Retrospective Study in Japan.

Authors:  Nobuyoshi Fukumitsu; Hitoshi Ishikawa; Takeshi Arimura; Hitoshi Wada; Tomoaki Okimoto; Yoshitaka Sato; Hiromitsu Iwata; Shosei Shimizu; Hideyuki Sakurai
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

Review 8.  Role of radiation therapy for renal tumors.

Authors:  Bhupesh Parashar; Kanhu Charan Patro; Michael Smith; Shruthi Arora; Dattatreyudu Nori; A Gabriella Wernicke
Journal:  Semin Intervent Radiol       Date:  2014-03       Impact factor: 1.513

9.  Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.

Authors:  Philip H Gutin; Fabio M Iwamoto; Kathryn Beal; Nimish A Mohile; Sasan Karimi; Bob L Hou; Stella Lymberis; Yoshiya Yamada; Jenghwa Chang; Lauren E Abrey
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-01-23       Impact factor: 7.038

10.  Salvage robot-assisted partial nephrectomy for the management of renal cell carcinoma following failed stereotactic radiotherapy.

Authors:  Michael A Gorin; Vladislav Gorbatiy; Charles Glenn; Samir P Shirodkar; Scott M Castle; Merce Jorda; Raymond J Leveillee
Journal:  JSLS       Date:  2012 Jan-Mar       Impact factor: 2.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.